Table 3.

Correlation Analyses of Clinical Characteristics with EV Number and TGF-β Levels (Total and Active) in PLWH and HIV-Negative Individuals

	EV Number [Correlation (P Value)]		TGF-β, Active [Correlation (P Value)]		TGF-β, Total [Correlation (P Value)]
	HIV-Negative Individuals (N = 30)	PLWH (N = 43)	HIV-Negative Individuals (N = 30)	PLWH (N = 43)	HIV-Negative Individuals (N = 30)	PLWH (N = 43)
Age, yr	0.0154 (0.9357)	0.2284 (0.1407)	−0.0036 (0.9851)	0.3061 (0.0459)	−0.0188 (0.9213)	0.3241 (0.0340)
White	−0.5874 (0.0006)	−0.0978 (0.5328)	−0.5155 (0.0036)	−0.1303 (0.4049)	−0.5115 (0.0039)	−0.1380 (0.3776)
Sex	−0.0350 (0.8544)	−0.1043 (0.5058)	−0.2448 (0.1923)	−0.2041 (0.1894)	−0.2565 (0.1713)	−0.1508 (0.3343)
Pack-years	0.2855 (0.1489)	0.3166 (0.0386)	0.1580 (0.4313)	0.3532 (0.0201)	0.2563 (0.1970)	0.3346 (0.0283)
Cocaine usage	0.7279 (5.2 × 10−6)	0.1495 (0.3388)	0.6123 (3.2 × 10−4)	0.1416 (0.3652)	0.7742 (5.2 × 10−7)	0.0747 (0.6340)
CD4, cell count/μl*	—	0.0868 (0.6200)	—	0.4319 (0.0096)	—	0.3802 (0.0243)
Viral load, copies/ml*	—	0.1507 (0.3666)	—	−0.1056 (0.5281)	—	−0.1514 (0.3641)
FVC% after BD*	0.2546 (0.1911)	0.2420 (0.1325)	0.1701 (0.3869)	0.1032 (0.5264)	0.0714 (0.7182)	0.0790 (0.6280)
FEV1% predicted after BD*	0.3930 (0.0386)	0.0203 (0.9009)	0.1276 (0.0.5177)	0.0110 (0.9462)	0.0959 (0.6271)	−0.0010 (0.9950)
FEV1/FVC after BD*	0.3039 (0.1159)	−0.4951 (0.0012)	−0.1771 (0.3674)	−0.3723 (0.0180)	−0.0767 (0.6981)	−0.3421 (0.0307)
DlCO% predicted*	−0.0099 (0.9608)	−0.3515 (0.0305)	0.3636 (0.0623)	−0.2978 (0.0694)	0.2883 (0.1447)	−0.2881 (0.0794)
PASP, mm Hg*	—	0.3456 (0.0663)	—	0.5087 (0.0048)	—	0.6189 (0.0003)
EV number × 1010*	—	—	0.2948 (0.1277)	0.5068 (0.0007)	0.3637 (0.0571)	0.5307 (0.0004)

^*Spearman rank correlation analysis was adjusted for sex and race.